![Peter J. Levine](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter J. Levine
Plus aucun poste en cours
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Ben A. Hitt | M | - |
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | 13 ans |
Annette Fribourg | F | - |
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | - |
Reid Adler | M | 70 |
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | 10 ans |
Brian C. Mansfield | M | - |
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | - |
Greg P. Bertenshaw | M | - |
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | - |
Ping F. Yip | M | - |
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | - |
Partha Seshaiah | M | - |
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | - |
Paolo Lecchi | M | - |
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | - |
John M. Peltier | M | - |
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | - |
Candice Miller | F | - |
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 10 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Peter J. Levine
- Réseau Personnel